Clinical Trials on Dubouitz Syndrome

Total 34145 results

Grupo Cooperativo de Estudio y Tratamiento de las...
Celgene Corporation; Germans Trias i Pujol Hospital; Hospital Son Llatzer

Unknown

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Myelodysplastic Syndromes

Spain
Samsung Medical Center

Completed

Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
University Hospital, Toulouse
National Cancer Institute, France

Completed

PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. (PREDICTOR)

Myelodysplastic Syndromes

France, Monaco
Hoffmann-La Roche

Completed

A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Thailand
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry (MORE)

Myelodysplastic Syndrome

Italy
Celgene

Completed

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Italy, United Kingdom, Germany, Australia, Bulgaria, France, Greece, Hungary, Netherlands, Poland, Spain
Celgene

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Celgene

Completed

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
University of Florida
Gateway for Cancer Research; Cellworks Group Inc.

Withdrawn

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Masonic Cancer Center, University of Minnesota
Mayo Clinic

Completed

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Lixte Biotechnology Holdings, Inc.

Unknown

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Weill Medical College of Cornell University
Sunesis Pharmaceuticals

Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Myelodysplastic Syndrome

United States
Seagen Inc.

Terminated

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Myelodysplastic Syndrome

United States
Associazione Qol-one

Terminated

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Myelodysplastic Syndromes

France, Italy, Greece
Helsinn Healthcare SA

Completed

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Terminated

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. (EXPHAR)

Myelodysplastic Syndrome

Belgium
Boehringer Ingelheim

Terminated

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Association pour la recherche sur les Affections...

Completed

Biological Predictive Factors of Response to ESA in Low Risk MDS Patients

Myelodysplastic Syndromes
Larry Cripe, MD
Celgene Corporation; Ortho Biotech Clinical Affairs, L.L.C.; Walther Cancer Institute

Terminated

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Mirati Therapeutics Inc.

Completed

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Withdrawn

Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Completed

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Washington University School of Medicine

Completed

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (MDS)

Myelodysplastic Syndromes

United States
Weill Medical College of Cornell University

Completed

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

Myelodysplastic Syndrome

United States
Xian-Janssen Pharmaceutical Ltd.

Completed

An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

China
Janssen-Cilag International NV

Completed

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

France, Germany, Bulgaria, Greece, Russian Federation
Genzyme, a Sanofi Company

Terminated

A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Swiss Group for Clinical Cancer Research

Completed

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Switzerland
Eisai Inc.

Terminated

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Myelodysplastic Syndromes

United States
Neal Young, M.D.

Completed

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

Myelodysplastic Syndrome

United States
PETHEMA Foundation
Roche Pharma AG; Celgene Corporation

Terminated

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome (SIMIDIS)

Myelodysplastic Syndrome

Spain
Groupe Francophone des Myelodysplasies
Genzyme, a Sanofi Company

Completed

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Myelodysplastic Syndromes

United States
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Duke University
Celgene Corporation

Completed

Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Eisai Inc.

Completed

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States, Canada
Seoul National University Hospital

Completed

Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome (H-1012-015-342)

Myelodysplastic Syndromes

Korea, Republic of
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Myelodysplastic Syndromes

Italy
Basque Health Service

Unknown

Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy

Myelodysplastic Syndrome

Spain
Cooperative Study Group A for Hematology

Unknown

Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (RICandDLI)

Myelodysplastic Syndrome

Korea, Republic of
Amgen

Completed

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes
Tel-Aviv Sourasky Medical Center

Unknown

Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) (IMDS001)

Myelodysplastic Syndrome

Israel
Groupe Francophone des Myelodysplasies

Unknown

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Myelodysplastic Syndromes

France
Novacea

Unknown

Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1

United States
Centre Hospitalier Universitaire de Besancon

Unknown

Abdominal Compartment Syndrome : Diagnostic and Prognostic Value of CT Findings - a Prospective Study (SCANAPIV)

Intra-Abdominal Hypertension | Abdominal Compartment Syndrome

3

Subscribe